Case Report: Immune checkpoint inhibitor–induced multiorgan vasculitis successfully treated with rituximab

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer. ICIs a unique side effect profile, generally caused by inflammatory tissue damage, with clinical features similar to autoimmune conditions. Acute kidney injury from has been well studied; incidence ranges 1% 5%, higher when combination ICI therapies are used. Although overall reported ICI-associated glomerulonephritis is less than 1%, vasculitis most commonly ICI-related glomerulonephritis. Other biopsy findings include thrombotic microangiopathy, focal segmental glomerulosclerosis, minimal change disease, and IgA nephropathy secondary amyloidosis. We report case in which woman previously treated PD-L1 inhibitor durvalumab for locally advanced non-small cell lung cancer pre-existing antineutrophil cytoplasmic (anti-PR3) antibody who later developed multi-organ after exposure, was successfully rituximab, continued remission 3 years.